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SUMMARY 
Endogenous depressives with abnormal dexamethasone suppression tests (DSTs) 
respond better to somatic antidepressant treatments than those with normal DSTs. 
Whether the DST also aids in the selection of specific antidepressants has not been deter- 
mined. A pilot report suggested that patients with abnormal DSTs might be noradrena- 
line-deficient and respond preferentially to imipramine or desipramine, whereas those 
with normal DSTs might be serotonin-deficient and respond best to amitriptyline or 
clomipramine. Attempting to replicate this observation, we studied 26 patients diagnosed 
with Research Diagnostic Criteria as major depressive disorder, endogenous subtype, and 
with DSM-III as having melancholia. All were drug-free during baseline evaluation. All had 
abnormal DST results, with post-dexamethasone plasma cortisol levels exceeding 5 gg/dl. 
We treated subjects with either imipramine or amitriptyline and compared clinical 
response with weekly Hamilton Depression Rating Scales, completed by raters blind to 
both DST results and the research question. Therapeutic plasma levels were documented. 
We found no significant differences in treatment response between the subgroups. 
Twenty of the 26 subjects did well. The imipramine-treated group failed to have either 
earlier response or better final outcome. These data fail to replicate suggestions that DST 
results assist in the selection of either imipramine or amitriptyline. 
INTRODUCTION 
The dexamethasone suppression test (DST) is a remarkably specific labo- 
ratory marker of endogenous depression (melancholia) (Brown et al. 1979; 
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Schlesser et al. 1979; Carroll et al. 1981a). An abnormal DST occurs when 
patients have early escapes from suppression of plasma cortisol secretion fol- 
lowing a midnight dose of 1 mg dexamethasone. These premature escapes are 
not due to changes in dexamethasone metabolism (Carroll et al. 1980). 
Instead, they presumably reflect disinhibition of the limbic-hypothalamic- 
pituitaryadrenal axis (Carroll et al. 1976). The DST has thus far been used 
mostly for nosological purposes in patients with major affective syndromes or 
related variants. Other clinical applications have been described, however. 
Greden et al. (1980a) reported that if abnormal DSTs fail to normalize with 
antidepressant treatment, early relapse is likely. Goldberg (1980) used a still- 
unproven modification of the DST (in which one plasma cortisol sample is 
drawn 34 h after administering dexamethasone), and suggested that antide- 
pressant medications might be safely discontinued once the test had normal- 
ized. Gold et al. (1980) agreed with Greden et al. (1980a) that treatment 
should be continued if the DST failed to normalize, but felt that Goldberg’s 
suggestion was still premature. Greden and Carroll (1979) and Carman et al. 
(1980) used the DST to assist with diagnosis and treatment of patients with 
catatonia, since non-suppression helped identify those with affective disorder 
rather than schizophrenia. The DST has similarly been used to help identify 
significant affective syndromes in borderline patients (Carroll et al. 1981b). 
Finally, several reports describe how periodic repetitions of the DST can be 
used to serially monitor clinical response to electroconvulsive treatments 
(ECT), and all agree that the test progressively normalized among responders 
(Dysken et al. 1979; Albala et al. 1980,198l). 
It is uncertain whether the DST predicts response to specific antidepres- 
sant medications. An early report (McLeod 1972) suggested that patients 
with abnormal DST results had poor responses to tricyclic antidepressants. 
Subsequent studies have consistently concluded that abnormal DST results 
predict better response to tricyclic antidepressants, at least among non-delu- 
sional depressives. Brown and colleagues (Brown et al. 1979; Brown and 
Shuey 1980a) found that 82% of endogenous depressives with abnormal DSTs 
had good clinical responses, compared to only 37% of those with a normal 
test. Greden et al. (1980b) found similar trends. Carman and associates 
(1980) concluded that the DST was better than clinicians’ judgements in pre- 
dicting the response of depressed catatonics to thymoleptic agents. 
In an expansion of their initial findings, Brown et al. (1980b) later sug- 
gested that abnormal DSTs might assist in the precise selection of antidepres- 
sants. Specifically, they reported that patients who had abnormal non-sup- 
pressive DSTs responded well after 2 weeks to desipramine or imipramine 
treatments, but poorly to amitriptyline or clomipramine. They felt these 
findings conformed to the hypothesis that depressed patients who have 
abnormal DSTs might be noradrenaline-deficient and those with normal 
DSTs might be serotonin-deficient. Differential drug response would then 
occur because antidepressants presumably differ in their respective effects 
upon noradrenergic or serotonergic reuptake (Iverson and MacKay 1979). 
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If clinicians were able to use the DST to assist treatment selection, the 
practical value of the test would increase greatly. To study this issue, we 
attempted to replicate the portion of the observations by Brown et al. (1980b) 
that suggested that abnormal DST results predicted better response to imi- 
pramine than to amitriptyline. In contrast to their findings, we failed to 
identify any significant differences in treatment response. 
METHODS 
Twenty-six subject (Ss) were hospitalized on the Clinical Studies Unit 
(CSU), a lo-bed research unit specializing in affective disorders, located 
within the University of Michigan Department of Psychiatry. All Ss provided 
informed consent. Baseline evaluations occurred following a drug-free period 
of at least lo-14 days. The evaluation consisted of 2 independent, unstruc- 
tured clinical interviews, a structured interview using the Schedule for Affec- 
tive Disorders and Schizophrenia (SADS) (Spitzer and Endicott 1975), a 
family diagnostic interview, a review of previous medical records, and a tho- 
rough physical and laboratory screening. Each subject met DSM-III (1980) 
criteria for melancholia and Research Diagnostic Criteria (RDC) (Spitzer et 
al. 1977) for Major Depressive Disorder, primary and endogenous subtypes. 
The dexamethasone suppression test, described in detail elesewhere (Car- 
roll et al. 1981), was considered abnormal if any of 3 post-dexamethasone 
plasma cortisol concentrations (08.00, 16.00, 23.00 h) exceeded 5 bg/dl. 
Samples were analyzed using a modification of Murphy’s (1967) competitive 
protein-binding technique. All investigators, clinicians and raters were blind 
to DST results until after patients were discharged. Because the research 
question was formulated retrospectively, they were also blind to the study 
question. 
Treatments were selected solely on clinical grounds. Nineteen subjects 
received imipramine and 7 were treated with amitriptyline. The discrepancy 
in subgroup size is explained by the retrospective nature of the study. Thera- 
peutic tricyclic plasma levels were documented for each subject. No other 
psychotropic medications were prescribed. The groups did not differ signif- 
icantly on the basis of unipolar or bipolar history. Treatment progress was 
monitored with weekly 17-item Hamilton Depression Rating Scale (HDRS) 
scores (Hamilton 1960). We assessed response by calculating the percentage 
of reduction from baseline HDRS scores and comparing imipramine-treated 
patients with amitriptyline-treated patients at 2, 3, 4 weeks and at discharge. 
We operationally defined “good treatment response” as at least a 50% reduc- 
tion from baseline HDRS, and a final HDRS score of 13 or less, and also 
compared subgroups using this criterion. 
RESULTS 
Comparisons between the two subgroups are displayed in Table 1. Anti- 
depressant plasma levels and ratios between imipramine/desipramine and 
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TABLE 1 
COMPARISON BETWEEN IMIPRAMINE (IMI) AND AMITRIPTYLINE (AMI) TREAT- 
MENTS IN ENDOGENOUS DEPRESSIVES WITH ABNORMAL DEXAMETHASONE 
SUPPRESSION TEST 
Item IMI-treated + AMI-treated + 
abnormal DST abnormal DST 
(N = 19) (N = 7) 








cortisol (pg/dl) a 











25.7 + 4.9 
13.1 f 5.7 
4.7 + 1.4 
9.6 * 7.7 
38.9 3~ 26.9 
45.9 f 19.8 
58.6 + 30.3 
62.5 + 29.7 
29.3 + 5.2 
16.8 f 9.4 
4.3 + 0.8 
10.0 + 9.4 
39.0 + 36.5 
36.8 + 30.8 
61.7 + 34.7 









a The highest plasma cortisol concentration from each test was used. Logarithmic trans- 
formations of these concentrations were used for statistical analysis, but actual values 
are presented in this table. 
amitriptyline/nortriptyline, respectively, are shown in Table 2. As illustrated 
in Table 1, the imipramine-treated subjects did not differ significantly from 
the amitriptyline-treated subjects on the basis of severity (baseline HDRS 
scores), baseline post-dexamethasone plasma cortisol values, or length of 
treatment prior to discharge. When treatment responses between the two 
groups were compared at weekly intervals and at final evaluation, there were 
also no significant differences. Indeed, at the completion of this hospital 
course of treatment, the patients with abnormal DSTs who received amitrip- 
tyline had a 69% reduction, thus showing slightly more improvement than 
the imipramine-treated group with a 62% reduction. Furthermore, 20 of the 
26 total subjects (77%) had “good clinical response” as operationally-defined 
(14 of 19 in the imipramine-treated group and 6 of 7 in the amitriptyline- 
treated group). Thus, most Ss did well regardless of selected treatment, and 
there were again no significant differences between the imipramine- and ami- 
triptyline-treated subgroups (chi-squared = 0.38, df = 1). These data do not 
support the claim that abnormal DSTs predict a better response to imipra- 

















































































































































































































































































































































































































































































































































































































































































Had we confirmed that DST results helped select the most effective anti- 
depressant medication, the implications would have been exciting. Our fail- 
ure to replicate the report of Brown et al. (1980b) is thus disappointing. What 
accounts for this discrepant result? One obvious consideration is that base- 
line DST abnormalities do not predict better final response to imipramine, 
but might predict earlier improvement with eventual “washout” of differ- 
ences. This possibility had credence because Brown et al. (1980b) conducted 
a single evaluation after only 2 weeks of treatment. We found no differences 
even at 2 weeks, however. At 3 weeks, the imipramine-treated group did 
have slightly greater improvement than the amitriptyline-treated subjects, 
but the inverse actually occurred at 4 weeks and at discharge. In conclusion, 
the evidence for DST results predicting either earlier response or better ulti- 
mate response to imipramine is weak or non-existent. 
The proposed hypothesis that 2 relatively-distinct biochemical subtypes of 
endogenous depression are being treated - noradrenaline (NA)-deficient and 
serotonin (5-HT)-deficient - might also be flawed and meaningless. Stewart 
et al. (1980), e.g., designed a study to test this hypothesis by comparing ini- 
tial responses to desipramine (DMI) with later responses to clomipramine if 
Ss failed to respond to DMI. They found that DMI, a drug which presumably 
blocks primarily neuronal adrenergic reuptake, produced improvement in 
almost all Ss. They therefore had to cancel the clomipramine portion of the 
study. Still another perspective of this same issue is that the serotonin vs. 
noradrenaline hypothesis might have validity, but cannot be tested in drug 
trials because of serious flaws in claims that various antidepressants pre- 
dominantly effect one or the other of the two systems. Iverson and Mackay 
(1979) emphasized that most of the current popular tricyclic antidepres- 
sants - including those used by Brown et al. (1980b) in their study and 
by us in this study - act with almost equal potency on both NA and 5-HT 
mechanisms, despite prevailing beliefs to the contrary. Although effects 
on NA uptake occur at drug concentrations lower than those affecting 
5-HT uptake, the spectrum of activity clearly covers both. Even clomipramine, 
which Brown et al. (1980b) utilized as a more perfect “serotonergic blocker”, 
has some blocade of NA reuptake. Imipramine and amitriptyline are also 
both demethylated to the active compounds desmethylimipramine and nor- 
triptyline, respectively. Changes in the ratios between parent compounds and 
these secondary amine metabolites further alter the spectrum of reuptake 
blockade. New antidepressants, such as maprotiline and fluoxetine, are sig- 
nificantly “cleaner” than traditional ones in their relative blockade potencies. 
Perhaps the same study strategy can be repeated in the future with these 
agents. Even then, investigators need to recognize that the mechanism of 
action of antidepressants is still unknown. A growing body of evidence sug- 
gests, for example, that the major effects of antidepressants might be due to 
downregulation of alpha-2-adrenergic presynaptic receptors, or decreased 
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sensitivity of postsynaptic beta-noradrenergic receptors and have little to do 
with blockade of reuptake (Crews and Smith 1978; Sulser et al. 1978; Maas 
and Huang 1980). 
Endogeneous depressives with abnormal DSTs, when compared with those 
with normal DSTs, seem to have a better response to somatic antidepressants 
in general. This finding is clinically meaningful. Patients with abnormal DSTs 
should receive an established somatic antidepressant treatment. Conclusions 
about which specific treatment, however, cannot yet be gleaned from the 
DST. 
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